Trials / Completed
CompletedNCT01709487
Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy
Feasibility Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Jules Bordet Institute · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
First line treatment for advanced ovarian carcinoma hyperthermic intraperitoneal chemotherapy (HIPEC) after optimal debulking.
Detailed description
Addition of HIPEC to the standard first line treatment of ovarian carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | HIPEC | HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2015-10-01
- Completion
- 2015-10-01
- First posted
- 2012-10-18
- Last updated
- 2016-02-24
Locations
2 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT01709487. Inclusion in this directory is not an endorsement.